**Note: the release below is a special early release from the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022, Lisbon, 23-26 April). Please credit the conference if you use this story**
New data to be presented at this year’s European Congress of Clinical Microbiology & Infectious Diseases (ECCMID 2022, Lisbon, 23-26 April) shows that participants taking the new anti-COVID drug molnupiravir eliminate actively infectious SARS-CoV-2 virus by day 3 of starting therapy, while many participants who received placebo took up to 5 days and in some cases longer to achieve this. The study is by Dr Julie Strizki and colleagues of the pharmaceutical company MSD, a trade name of Merck & Co., Inc, Kenilworth, NJ, USA, who manufacture molnupiravir (brand name Lagevrio).
Molnupiravir is an oral antiviral prodrug with broad activity against coronaviruses, including SARS-CoV-2 and its variants of concern. The randomised, placebo-controlled, double-blind phase 2/3 MOVe-OUT trial (already published in NEJM, see link below) confirmed superiority of molnupiravir over placebo in non-hospitalised adults with mild/moderate COVID-19 at risk of progression to severe disease, provided they started therapy within five days of symptom onset. The drug has been granted an emergency use authorisation by the by the US Food and Drug Administration (FDA) and is also authorised for use in the UK, Australia, and Japan and 12 other jurisdictions.*
PCR testing was used to determine SARS-CoV-2 RNA viral loads from nasopharyngeal swabs collected on days 1 (baseline), 3, 5 (end-of-treatment visit), 10, 15, and 29. This new study reports the final analyses of virologic outcomes from this trial. The analysis includes participants with infectious virus isolated at baseline and who had a post-baseline SARS-CoV-2 RNA sample available (n=92 molnupiravir, n=96 placebo).
Results demonstrated that on day 3 of treatment, infectious SARS-CoV-2 was detected in zero of 92 of participants with infectious virus at baseline who received molnupiravir, compared with 21.8% (20/96) of participants who received placebo. At Day 5, virus was detected in 0.0% (n=0/91) in the molnupiravir arm compared with 2.2% (n=2/89) in the placebo arm. At Day 10, no virus was detected in either arm for patients with infectious virus at baseline.
Dr Strizki concludes: “This analysis of the final virologic outcome data from MOVe-OUT confirms previous observations demonstrating that a 5-day treatment course of twice-daily 800 mg molnupiravir results in a more rapid decline in viral RNA and faster elimination of infectious virus than placebo... This study provides additional evidence that molnupiravir helps those infected clear SARS-CoV-2 faster than placebo, and supports MOVe-OUT’s primary finding that molnupiravir can lower the risk of progression to serious illness in this high-risk cohort.”
Molnupiravir is now in the process being submitted to global regulatory authorities for emergency use authorisation or approval in other countries and jurisdictions, such as the European Medicines Agency (EMA) and is being studied in a Phase 3 trial, MOVe-AHEAD, to evaluate it in a prophylaxis setting.
All requests for interviews with the study authors should be MSD Media Office Sienna Choi T) +1 908 873 4311 E) firstname.lastname@example.org and Courtney Ronaldo T) +1 (908) 442-5695 E) email@example.com
Alternative contact in the ECCMID Media Centre Tony Kirby of Tony Kirby PR T) +44 7834 385827 E) firstname.lastname@example.org
Conflict of interest statement: all authors on this study are employees of Merck & Co., Inc., Kenilworth, NJ, USA, the manufacturer of molnupiravir
This press release is based on late breaker abstract 4514 at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) Annual Meeting to be held in Lisbon from 23-26 April. The material has been peer reviewed by the congress selection committee. There is no full paper at this stage, but the authors are happy to answer your questions. The research has not yet been submitted for publication.
*In addition to the USA, the UK, Japan and Australia, molnupiravir is also authorised in Colombia, Mexico, Panama, Peru, Costa Rica, Taiwan, Thailand, South Korea, United Arab Emirates, Bahrain, Ukraine, and Qatar (total 16 jurisdictions)
See abstract for figures and tables.
All authors on this study are employees of Merck & Co., Inc., Kenilworth, NJ, USA, the manufacturer of molnupiravir